WealthAi | $1,000,000 | (Jan 30, 2026)
Checkbox | $23,000,000 | (Jan 30, 2026)
PaleBlueDot AI | $150,000,000 | (Jan 30, 2026)
Certified by Founder
Lodge
Poplar Therapeutics
start up
United States
- Boston, MA
- 09/01/2026
- Series A
- $50,000,000
Poplar Therapeutics is a clinical-stage immunology company developing a new class of anti-IgE therapy to challenge convention in allergic disease treatment. Its lead program, PHB-050, is a next-generation anti-IgE antibody with a unique triple-action design currently being studied in atopic diseases. Poplar is pursuing the bold idea that IgE can be rapidly driven toward zero, with the goal of helping people with IgE-mediated conditions move from fear toward freedom.
- Industry Biotechnology Research
- Website https://poplartx.com/
- LinkedIn https://www.linkedin.com/company/poplar-therapeutics/
Mesh Security | $12,000,000 | (Jan 30, 2026)
Datalinx AI | $4,200,000 | (Jan 30, 2026)
Ressio Software | Undisclosed Amount | (Jan 30, 2026)
Co-reactive | $7,754,157 | (Jan 30, 2026)
Arkero | $6,000,000 | (Jan 30, 2026)
Twogee Biotech | $2,575,886 | (Jan 30, 2026)
Levellr | $2,500,000 | (Jan 30, 2026)
Indigo(1) | $50,000,000 | (Jan 30, 2026)
heyData | $16,500,000 | (Jan 30, 2026)